Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.

Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP.

Oncologist. 2019 Sep;24(9):1149-e807. doi: 10.1634/theoncologist.2019-0331. Epub 2019 May 31.

2.

Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.

Krook MA, Barker H, Chen HZ, Reeser JW, Wing MR, Martin D, Smith AM, Dao T, Bonneville R, Samorodnitsky E, Miya J, Freud AG, Monk JP, Clinton SK, Roychowdhury S.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):624-632. doi: 10.1038/s41391-019-0145-2. Epub 2019 May 1.

PMID:
31043681
3.

Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial.

Focht BC, Lucas AR, Grainger E, Simpson C, Fairman CM, Thomas-Ahner JM, Buell J, Monk JP, Mortazavi A, Clinton SK.

Ann Behav Med. 2018 Apr 19;52(5):412-428. doi: 10.1093/abm/kax002.

4.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Lara PN Jr, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI.

Cancer Treat Res Commun. 2018;16:18-23. doi: 10.1016/j.ctarc.2018.04.005. Epub 2018 Apr 28.

5.

Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S.

Oncotarget. 2017 Sep 1;8(44):75822-75833. doi: 10.18632/oncotarget.20616. eCollection 2017 Sep 29.

6.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI.

Clin Genitourin Cancer. 2017 Dec;15(6):635-641. doi: 10.1016/j.clgc.2017.05.014. Epub 2017 May 10.

7.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd.

J Immunol. 2015 Sep 1;195(5):1995-2005. doi: 10.4049/jimmunol.1400084. Epub 2015 Aug 3.

8.

Real-time scintigraphic assessment of intravenous radium-223 administration for quality control.

Wright CL, Monk JP 3rd, Murrey DA Jr, Hall NC.

Biomed Res Int. 2015;2015:324708. doi: 10.1155/2015/324708. Epub 2015 Feb 18.

9.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI.

Int J Cancer. 2015 Apr 15;136(8):1856-62. doi: 10.1002/ijc.29212. Epub 2014 Oct 8.

10.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

11.

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ.

J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500. Epub 2014 Mar 3.

12.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).

Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology.

Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285. Epub 2013 Jul 31.

13.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr.

Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17.

14.

A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Mortazavi A, Ling Y, Martin LK, Wei L, Phelps MA, Liu Z, Harper EJ, Ivy SP, Wu X, Zhou BS, Liu X, Deam D, Monk JP, Hicks WJ, Yen Y, Otterson GA, Grever MR, Bekaii-Saab T.

Invest New Drugs. 2013 Jun;31(3):685-95. doi: 10.1007/s10637-012-9863-1. Epub 2012 Jul 31.

15.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ.

J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.

16.

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ; Cancer and Leukemia Group B.

Cancer. 2012 Sep 1;118(17):4139-47. doi: 10.1002/cncr.26732. Epub 2011 Dec 16.

17.

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.

Monk JP, Villalona-Calero M, Larkin J, Otterson G, Spriggs DS, Hannah AL, Cropp GF, Johnson RG, Hensley ML.

Invest New Drugs. 2012 Aug;30(4):1676-83. doi: 10.1007/s10637-011-9731-4. Epub 2011 Aug 9.

18.

Motorcycle-related trauma in Alberta: a sad and expensive story.

Monk JP, Buckley R, Dyer D.

Can J Surg. 2009 Dec;52(6):E235-40.

19.

High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.

Rathmell WK, Monk JP.

Urology. 2008 Sep;72(3):659-63. doi: 10.1016/j.urology.2008.05.009. Epub 2008 Jul 23.

PMID:
18649931
20.

A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen.

Grainger EM, Schwartz SJ, Wang S, Unlu NZ, Boileau TW, Ferketich AK, Monk JP, Gong MC, Bahnson RR, DeGroff VL, Clinton SK.

Nutr Cancer. 2008;60(2):145-54. doi: 10.1080/01635580701621338.

PMID:
18444145
21.

Information seeking and satisfaction with physician-patient communication among prostate cancer survivors.

Cegala DJ, Bahnson RR, Clinton SK, David P, Gong MC, Monk JP 3rd, Nag S, Pohar KS.

Health Commun. 2008;23(1):62-9. doi: 10.1080/10410230701806982.

PMID:
18443993
22.

Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center.

Grainger EM, Kim HS, Monk JP, Lemeshow SA, Gong M, Bahnson RR, Clinton SK.

Urol Oncol. 2008 Mar-Apr;26(2):125-32. doi: 10.1016/j.urolonc.2007.01.016. Epub 2007 Oct 18.

PMID:
18312929
23.

Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.

Kondadasula SV, Varker KA, Lesinski GB, Benson DM Jr, Lehman A, Olencki T, Monk JP, Kendra K, Carson WE 3rd.

Cancer Immunol Immunother. 2008 Aug;57(8):1137-49. doi: 10.1007/s00262-007-0444-7. Epub 2008 Jan 10.

PMID:
18193422
24.

Gastrointestinal stromal tumors involving the prostate: presentation, course, and therapeutic approach.

Arce-Lara C, Shah MH, Jimenez RE, Patel VR, Benson DM Jr, Clinton SK, Monk JP.

Urology. 2007 Jun;69(6):1209.e5-7.

PMID:
17572224
25.

Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma.

Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH.

Nat Clin Pract Nephrol. 2007 May;3(5):287-93.

PMID:
17457362
26.

Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.

Varker KA, Kondadasula SV, Go MR, Lesinski GB, Ghosh-Berkebile R, Lehman A, Monk JP, Olencki T, Kendra K, Carson WE 3rd.

Clin Cancer Res. 2006 Oct 1;12(19):5850-8.

27.

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.

Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, Guttridge D, Rhoades C, Shah M, Criswell T, Caligiuri MA, Villalona-Calero MA.

J Clin Oncol. 2006 Apr 20;24(12):1852-9.

PMID:
16622259
28.

Below-knee PTFE bypass graft fatigue.

Fisher RK, Monk JP, Pandey VA, Harris PL.

Eur J Vasc Endovasc Surg. 1999 Sep;18(3):266-7. No abstract available.

29.
30.

Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Monk JP, Brogden RN.

Drugs. 1990 Sep;40(3):374-411. Review. Erratum in: Drugs 1991 Mar;41(3):377.

PMID:
2226221
32.

Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Saltiel E, Ellrodt AG, Monk JP, Langley MS.

Drugs. 1988 Oct;36(4):387-428. Review.

PMID:
3069435
33.

Sufentanil. A review of its pharmacological properties and therapeutic use.

Monk JP, Beresford R, Ward A.

Drugs. 1988 Sep;36(3):286-313. Review.

PMID:
2903821
34.
35.
36.

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Campoli-Richards DM, Monk JP, Price A, Benfield P, Todd PA, Ward A.

Drugs. 1988 Apr;35(4):373-447. Review.

PMID:
3292209
38.

Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Campoli-Richards DM, Lackner TE, Monk JP.

Drugs. 1987 Oct;34(4):411-37. Review.

PMID:
3315624
40.
42.

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Monk JP, Campoli-Richards DM.

Drugs. 1987 Apr;33(4):346-91. Review.

PMID:
3297617
44.

Interference of an oxprenolol metabolite with screening tests for 5-hydroxyindole in urine.

John VA, Monk JP, Dorhofer G.

Clin Chem. 1983 Apr;29(4):743-4. No abstract available.

45.

Plasma profiles following single, oral, and rectal doses of phenylbutazone in healthy volunteers.

John VA, Monk JP, Hubbard J, Theobald W.

Biopharm Drug Dispos. 1983 Jan-Mar;4(1):95-9. No abstract available.

PMID:
6839007
46.

Supplemental Content

Support Center